Physician

Garth A Beinart, M.D.

According to 2025 Medicare claims, Garth Beinart, M.D. (NPI: 1396844262) practices medical oncology in the Houston-Pasadena-The Woodlands, TX market, with the plurality of this provider's patient population coming from Harris, TX. This provider's primary affiliated billing organization is MEDICAL CLINIC OF HOUSTON, L.L.P. (NPI: 1972539492; TIN: 74-1181532) and primary practice location at 77005-1713. Beinart is affiliated with the ACMG Health Systems, Inc. (ACO ID: A4749), participating under the MSSP model.

Beinart's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 425 traditional Medicare patients, billed 110,102 HCPCS/CPT codes, and received $2,754,698 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,652 prescription claims across 195 beneficiaries totaling $2,194,031 in drug costs, led by Welireg (Belzutifan). DME data shows 86 claims. Open Payments data shows 2 records totaling $38. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $686,243 to $2,754,698. Similarly, Part D prescription costs have risen steadily, from $635,704 to $2,194,031. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	317	59,642	$686,243
2016	357	41,354	$633,442
2017	377	54,874	$711,042
2018	384	53,833	$893,791
2019	427	76,422	$1,330,583
2020	406	70,335	$1,455,316
2021	398	88,368	$1,727,488
2022	417	92,103	$1,679,513
2023	389	72,492	$1,868,793
2024	425	110,102	$2,754,698

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	134	1,182	$635,704
2016	144	1,458	$1,062,724
2017	154	1,210	$962,640
2018	146	1,365	$1,498,236
2019	154	1,427	$1,367,220
2020	144	1,311	$1,463,270
2021	168	1,295	$1,309,291
2022	165	1,266	$1,882,901
2023	178	1,264	$1,662,335
2024	195	1,652	$2,194,031

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	31	98	$60,390
2016	N/R	50	$23,770
2017	N/R	64	$20,411
2018	N/R	47	$8,972
2019	N/R	36	$4,309
2020	N/R	51	$3,083
2021	N/R	72	$4,281
2022	N/R	90	$3,419
2023	N/R	58	$6,883
2024	N/R	86	$2,472

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	68	68	$128
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	296	1,079	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	132	299	$70
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	96	596	$62
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	66	190	$45

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Welireg	Belzutifan	20	600	$500,142
Revlimid	Lenalidomide	26	700	$366,110
Calquence	Acalabrutinib Maleate	25	750	$314,467
Abiraterone Acetate	Abiraterone Acetate	16	480	$60,235
Eliquis	Apixaban	46	2,220	$41,311

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	11	$997
J8521	Capecitabine, oral, 500 mg	N	N/R	24	$679
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	25	$471
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	26	$326

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$38	GE HEALTHCARE
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Garth A. Beinart, M.D.?

Tedicare shows public-source Medicare data for Garth A. Beinart, M.D. (NPI 1396844262), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Garth A. Beinart, M.D. have ACO affiliation data?

Garth A. Beinart, M.D. is shown with ACO affiliation data for ACMG Health Systems, Inc. (MSSP, ACO ID A4749).

What billing organization is linked to Garth A. Beinart, M.D.?

Garth A. Beinart, M.D. is linked to MEDICAL CLINIC OF HOUSTON, L.L.P. (billing NPI 1972539492) in the available physician profile data.

Does Garth A. Beinart, M.D. have Open Payments data?

Garth A. Beinart, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.